Provided by Tiger Trade Technology Pte. Ltd.

Anika Therapeutics

10.85
-0.0700-0.64%
Post-market: 10.850.00000.00%16:10 EST
Volume:223.73K
Turnover:2.46M
Market Cap:156.47M
PE:-4.73
High:11.30
Open:11.00
Low:10.82
Close:10.92
52wk High:18.07
52wk Low:7.87
Shares:14.42M
Float Shares:10.36M
Volume Ratio:2.20
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2918
EPS(LYR):-3.8302
ROE:-8.73%
ROA:-3.50%
PB:1.07
PE(LYR):-2.83

Loading ...

Anika Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
Yesterday

Anika Therapeutics CEO Steve Griffin to Present at Canaccord Genuity 2026 Musculoskeletal Conference

Reuters
·
Feb 19

Anika Therapeutics Inc. to Announce Fourth Quarter and Year-End Financial Results

Reuters
·
Feb 13

Medacta Group reports 18.5% revenue growth in 2025

Reuters
·
Feb 03

Anika Therapeutics Is Maintained at Outperform by Barrington Research

Dow Jones
·
Jan 09

Anika Therapeutics Announces CEO Transition and Governance Changes

TIPRANKS
·
Jan 09

Anika Therapeutics Names Steve Griffin CEO as Cheryl Blanchard Becomes Executive Chair

Reuters
·
Jan 08

Anika Therapeutics Inc - Cheryl Blanchard to Become Executive Chair of the Board

THOMSON REUTERS
·
Jan 08

Anika Therapeutics Inc - Stephen Griffin Appointed President and CEO

THOMSON REUTERS
·
Jan 08

Anika Therapeutics Announces Leadership Transition

GlobeNewswire
·
Jan 08

Anika Therapeutics Q3 Revenue USD 27.817 Million

Reuters
·
Nov 20, 2025

Anika Therapeutics Is Maintained at Outperform by Barrington Research

Dow Jones
·
Nov 07, 2025

Anika Therapeutics price target raised to $16 from $15 at Barrington

TIPRANKS
·
Nov 06, 2025

Anika Therapeutics Inc : Barrington Research Raises Target Price to $16 From $15

THOMSON REUTERS
·
Nov 06, 2025

Anika Therapeutics Reports Mixed Q3 2025 Results

TIPRANKS
·
Nov 06, 2025

Anika Q3 2025 Earnings Call Summary and Q&A Highlights: Regenerative Solutions Drive Growth Amid OEM Pricing Pressure

Earnings Call
·
Nov 05, 2025

Anika (ANIK) Q3 2025 Earnings Call Transcript

Motley Fool Transcribing
·
Nov 05, 2025

Anika Therapeutics Q3 Adj. EPS $0.04 Beats $(0.27) Estimate, Sales $27.800M Inline

Benzinga
·
Nov 05, 2025

Anika beats Q3 revenue estimates, maintains guidance

Reuters
·
Nov 05, 2025

BRIEF-Anika Therapeutics Q3 Revenue USD 27.817 Million

Reuters
·
Nov 05, 2025